Chapter 30: Antitubercular, Antifungal & Antiviral Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today, we are wading into what I like to call the danger zone of pharmacology.

We aren't dealing with your standard run -of -the -mill infections where you, pop a pill for five days and forget about it.

Not at all.

We are looking at the bugs that are stubborn,

the ones that hide in your DNA and the ones that have been stalking humanity since like the Stone Age.

It is a heavy lineup today.

We are rolling up our sleeves and tackling chapter 30 from the pharmacology,

a patient -centered nursing process approach text, specifically the 12th edition.

Right.

And I have to be honest, for a nursing student, this chapter is, it's usually a massive stumbling block.

Right.

The drug names are long.

The side effects can be quite severe and the treatment regimens are just, they're grueling.

Which is exactly why we're here.

Our mission today is to decode this.

We need to move past the flashcards.

If you're listening to this, you probably know that mycobacterium tuberculosis causes TB.

Great.

But do you know why we have to treat it with four drugs simultaneously?

That's the key question.

Do understand the specific mechanism that turns a patient's tears orange?

That is what we are unpacking.

We're looking at three distinct categories and at tuberculars, antifungals and antivirals.

Three distinct enemies and three very, very different battle plans.

So let's look at the roadmap.

We're going to start with tuberculosis, the ancient and resilient enemy.

Good place to start.

Then we'll shift to fungal infections, which you call the opportunistic invaders.

And we'll finish up with viruses, the intracellular hijackers.

And we will wrap it all up with a clinical judgment case study to see how this actually plays out in the real world.

Perfect.

Let's jump right into the first section, tuberculosis.

The text describes TB as being caused by the acid -fast bacillus mycobacterium tuberculosis.

Now, acid -fast bacillus sounds a little bit like lab trivia, but the text suggests it's actually really important for understanding the bug.

It's the defining characteristic.

When we say acid -fast, we are talking about the lab stain.

Most bacteria, you stain them, you wash them with acid, and the stain just comes right off.

But TB has this incredibly thick, waxy cell wall.

Like a shield.

Exactly.

So when you stain it and wash it with acid, the stain holds fast.

It stays red.

That waxy wall is also what makes it so incredibly resilient in the body.

It's like the bacteria is wearing a hazmat suit.

And historically, we thought we were winning the war against TB, right?

I mean, cases were declining for a long time.

They were until the mid -80s.

The text points out that decline stopped around 1985.

And what happened?

Well, the resurgence is attributed to a few specific factors.

The HIV epidemic was a major driver because it weakened immune systems across the population.

Right.

Then you have increased immigration from areas with high TB prevalence.

And the scariest factor,

the rise of multi -drug resistant TB or MDR TB.

And just to give our listeners a sense of the scale here, the text cites the World Health Organization.

TG is the 13th leading cause of death globally.

And after COVID -19, it is the leading cause of death from a single infectious agent.

That is a staggering statistic.

It is.

And in the U .S., while the active numbers might seem lower, the text says around 8 ,300 cases reported by the CDC in 2022.

The scary number is the latent population.

The hidden cases.

The hidden cases.

It's estimated that up to 13 million people in the United States have latent TB.

We really need to unpack that distinction because it confuses a lot of students.

Latent versus active.

What is actually happening in the body?

Okay.

So let's start with transmission.

You inhale the droplet nuclei.

Okay.

And we should specify these aren't big heavy droplets from a sneeze that just fall on the floor.

These are microstopic.

They can float in the air for hours.

You inhale them and they settle deep in the lungs.

So the bacteria is in the lungs.

Now what?

Right.

Now, if you have a healthy immune system, your body fights back.

Specifically, the macrophages, the big eater cells of the immune system, they surround the bacteria.

And they just eat it.

Well, they try.

But because of that waxy wall, they can't always kill it.

So instead, the body does the next best thing.

It builds a wall around the bacteria.

It forms a granuloma or what's called a tubercle.

So it puts the bacteria in prison.

Exactly.

A high security prison.

The bacteria is alive inside that little wall, but it is contained.

It can't replicate and it can't escape.

And that's latent TB.

That is latent TB infection.

The patient feels totally fine.

They have zero symptoms.

And critically, they are not infectious.

They cannot spread it

But the bacteria is just waiting.

It's waiting.

It's waiting.

If the immune system ever slips, if the prison guards fall asleep, so to speak, the bacteria breaks out.

That is when it becomes active TB disease.

Now the bacteria is multiplying its destroying lung tissue and the patient is very, very infectious.

And this connects directly to the high risk list in the text.

Who are the people whose prison guards are most likely to fall asleep?

The immunocompromise are at the absolute top of the list.

Patients with HIV are at massive risk because the virus destroys the very cells needed to keep TB in check.

Makes sense.

Also patients with diabetes, renal failure, or those taking immunosuppressants like corticosteroids or chemotherapy.

The text also mentions congregate settings.

Right.

And that makes perfect sense.

Prisons, nursing homes, homeless shelters, anywhere people are living in close quarters with potentially poor ventilation.

So if one person has

It spreads through the air to everyone else.

And often people in these settings have other risk factors like malnutrition or substance use issues.

Substance abuse is explicitly mentioned.

Specifically, injection drug use and alcohol use.

Why alcohol?

Alcohol is a big one because it suppresses the immune system directly and it often leads to malnutrition.

It creates the perfect storm for that latent TB to wake up.

So as a nurse, if you have a patient who fits this profile and the TB wakes up, what are you seeing?

What are the clinical manifestations?

It's a very distinct picture.

You are looking for a cough that just will not go away.

It's usually productive.

And the classic sign is hemoptysis.

Blood tinged sputum.

Blood tinged sputum.

That's the movie symptom.

You know, the character coughs into a handkerchief and there's this spot of blood.

Exactly.

But along with that, you have to look for the systemic signs.

Anorexia.

And that means a complete loss of appetite and significant unintentional weight loss.

They used to call it consumption.

That's why.

The body is literally being consumed by the infection.

And the night sweats.

Yes.

And I don't mean just feeling a bit warm at night.

I mean waking up and having to change the sheets because they are completely soaked.

Also, fever, chest pain, fatigue.

If you see that combination, chronic cough, weight loss, night sweats, your alarm bells should be ringing loud and clear.

Okay.

So we suspect it.

We get a sputum sample.

The lab does the acid fast stain.

It comes back positive.

Now we have to treat it.

And this is where the pharmacology gets really intense.

The text emphasizes one golden rule.

You never ever use single drug therapy for active TB.

Why is that?

Because mycobacterium tuberculosis is a master of mutation.

It is incredibly adaptable.

If you hit it with just one drug, you might kill 99 % of the bacteria.

But that 1 % that survives, they're the ones that had a natural random resistance to that drug.

They survive, they multiply, and suddenly the patient is sick again.

But this time the drug doesn't work at all.

Resistance develops that quickly.

Very, very quickly.

Back in the 1940s, when they first discovered streptomycin, they used it alone.

Patients got better for a few months and then they crashed and burned because the bacteria mutated.

So the strategy now is multi -drug therapy.

It's a shock and awe campaign.

It is.

We hit the bacteria with multiple mechanisms of action at the same time.

This drastically reduces the chance that the bacteria can survive and develop resistance.

It also shortens the duration of treatment, though shortens is a very relative term here.

Yeah, let's talk about that timeline.

This isn't a 10 -day course of amoxicillin.

Not even close.

We are talking about a marathon.

The standard regimen is divided into two phases.

The initial phase lasts for two months.

This is the aggressive phase where we are giving four drugs daily.

Four drugs every day.

Every day.

Then we move to the continuation phase, which lasts another four to seven months.

So we are looking at six to nine months minimum.

Minimum.

And if the patient has a drug resistance strain or if they have HIV co -infection, treatment can last up to two years.

Two years.

Imagine the difficulty of adherence there.

Taking a handful of pills every single day for nine months, especially when you might be feeling better after a month too.

That is the single biggest challenge in TB management.

Compliance.

Hands down.

Let's get into the drugs themselves.

The text highlights the core four.

The first -line drugs.

Isoniazid, rifampin, pyrazinamide, and ethambutol.

We need to break these down because each one has a specific personality and a specific set of risks.

Let's start with the prototype.

The captain of the team.

Isoniazid or INH.

This drug has been around since 1952 and it is still the primary anti -tubercular agent.

How does it work?

It's bactericidal, meaning it kills the bacteria.

Specifically, it inhibits the synthesis of mycolic acid.

The stuff in the waxy wall.

The exact stuff in that waxy wall we talked about.

Mycolic acid is the main ingredient.

INH stops the bacteria from building its wall and without the wall, it dies.

But INH comes with a very specific, very testable side effect profile.

It does.

And this is where the nursing implications start to pile up.

The big one is peripheral neuropathy.

Numbness, tingling, burning in the hands and feet.

Exactly.

And the mechanism behind it is fascinating.

INH is structurally very similar to pyridoxin, which is vitamin B6.

Okay.

When you take INH, it competes with vitamin B6 for the enzyme needed to metabolize it.

Essentially, the drug causes a vitamin B6 deficiency.

And since nerves need B6 to function properly.

You get neuropathy.

So the standard of care and the is very clear on this is that patients taking INH should receive oral vitamin B6 supplementation.

Usually about 25 to 50 milligram daily.

And that prevents it.

It prevents the neuropathy without interfering with the TB treatment at all.

It's a preventable side effect if the nurse is paying attention.

Okay.

What else for INH?

The other major organ at risk with INH is the liver.

Hepatotoxicity.

INH can cause drug induced hepatitis.

So we are monitoring liver enzymes.

Absolutely.

AST, ALT, and bilirubin.

You need a baseline before you start and you check them regularly.

If those enzymes sheet up, usually to three times the normal limit, you have to hold the drug.

And this leads to a critical patient education point.

No, alcohol.

That's a tough conversation.

If the patient has a history of alcohol use disorder.

It is, but it's non -negotiable.

Alcohol is hepatotoxic on its own.

Combining it with INH is like lighting a match in a gas station.

It dramatically increases risk of liver failure.

It also increases the risk of neuropathy because people who use alcohol heavily are often already B6 deficient.

The text also mentions some food interactions with INH.

Yes.

INH inhibits an enzyme called monoamine oxidase, similar to MAOI antidepressants.

So if a patient eats foods high in termine like aged cheese, cured meats, red wine, they can have a hypertensive crisis.

A spike in blood pressure.

A huge spike.

Also foods rich in histamine like tuna can cause a reaction like flushing and headache.

So a complicated diet, long duration, serious side effects.

Let's move to the second big gun.

Rifampin.

Rifampin is a rifamycin antibiotic.

It works by inhibiting bacterial RNA synthesis.

But what everyone, and I mean everyone, remembers about rifampin is the side effect.

The orange warning.

The red -orange discoloration of body fluids.

We are talking urine, sweat, tears, saliva.

Everything turns a shade of orange or red.

I can imagine that would be absolutely terrifying for a patient if they weren't warned.

It happens.

Doctor, I'm sweating blood.

That is why the education piece is so vital.

You have to tell them.

This is going to happen.

It is harmless.

Do not panic.

But there is a practical catch.

Yes.

The text notes that this discoloration can permanently stain soft contact lenses.

So if a patient wears contacts?

They need to switch to glasses for the entire duration of treatment.

Otherwise they will end up with permanently orange tinted lenses.

Rifampin is also a metabolic bully, isn't it?

The text mentions a lot of drug interactions.

Bully is a good word for it.

Yeah.

Rifampin is a potent inducer of the hepatic CYP450 enzyme system.

In plain English.

It revs up the liver's metabolism engine to high gear.

This means it chews up other drugs much, much faster than normal.

So if a patient is taking other medications?

Their effectiveness will plummet.

The classic example is oral contraceptives, birth control pills.

Rifampin metabolizes the hormones in so fast that they just stop working.

Oh, that's a big deal.

It's a huge deal.

Nurses must advise female patients to use a non -hormonal form of birth control, or they might end up with an unintended pregnancy while being treated for tuberculosis.

A nightmare scenario.

Okay.

Drug number three.

Pyrazinamide.

Pyrazinamide or PZA.

This is also back to recital.

And just like INH and Rifampin, it is hepatotoxic.

So now we have three drugs in Exactly.

You can see why monitoring those enzymes is so critical.

But PZA has a unique side effect involving joints, right?

Yes.

PZA inhibits the excretion of uric acid.

When uric acid builds up in the blood, it can deposit in the joints.

This can cause non -gouty polyarthralgia, which is just pain in multiple joints.

But in patients who are susceptible, it can trigger a full -blown gout attack.

Hot, swollen, incredibly painful joints.

Very same.

So we encourage fluids to help flush that uric acid out, and sometimes we have to manage the pain with something like NSAIDs.

And finally, the E in the group, ethambutol.

Ethambutol is helpful because it is not as hepatotoxic as the others.

However, it has a very specific toxicity of its own.

The eyes.

The eyes.

E for eye.

Exactly.

It can cause optic neuritis.

And what does that look like?

It manifests as a decrease in visual acuity, so things get blurry.

But specifically, it can cause a loss of red -green color discrimination.

That's wild.

So they literally lose the ability to tell red from green.

Yes.

So before starting ethambutol, and periodically during treatment, the patient needs a full ophthalmologic exam.

A real eye exam.

If a patient reports any vision changes, you stop the drug immediately.

Is it reversible?

If you catch it early, yes.

If you don't, it can cause permanent blindness.

The text also throws streptomycin into the mix.

This is an older drug, right?

It is.

It was the very first anti -tubercular drug discovered back in 1943.

It's an aminoglycoside antibiotic.

It's an injection, which makes it harder to administer long -term.

And it has pretty high toxicity.

What are the risks?

Ototoxicity and nephrotoxicity.

It damages the ears and the kidneys.

So hearing loss and kidney failure.

Specifically, it can affect the vestibulocochlear nerve.

So you get tinnitus ringing in the ears, hearing loss, and even balance issues.

And for the kidneys, you monitor BUN and creatinine closely.

So we don't use it much anymore.

Because of these toxicities, it's usually reserved for drug -resistant cases or when patients can't tolerate the first -line oral drugs.

Let's pivot to special populations.

The text highlights pregnancy, HIV, and pediatrics.

Starting with pregnancy, if these drugs are so toxic, particularly to the liver, can a pregnant patient even take them?

This is a classic case of risk versus benefit.

And the text is very clear.

The benefit of treating active TB in a pregnant female far outweighs the risk of the drug.

Oh yeah, untreated TB is far more dangerous to the fetus than the drugs are.

It can lead to low birth weight, preterm labor, and massive complications.

So do they use the standard regimen?

Mostly.

The initial treatment typically involves INH, refampin, and ethymutol.

They generally avoid streptomycin because it can cause congenital hearing loss in the baby.

But otherwise, the treatment goes on.

What about HIV co -infection?

The text calls this a dangerous combination.

It's lethal.

HIV weakens the immune system, allowing latent TB to quickly become active.

And in a terrible feedback loop, TB accelerates the progression of HIV.

So is it double whammy?

It is.

And the treatment is complex because rifamycins like refampin interact with many antiretroviral drugs used for HIV.

It requires expert management, but the core principle is that you treat the TB aggressively.

And for pediatrics?

Children get sick fast.

Their immune systems aren't fully developed.

If a child has latent TB, we treat it immediately to prevent active disease.

The big nursing role here is family education.

Adherence again.

Always adherence.

If a child stops taking the meds because they feel better, or because the parents struggle with the routine, the bacteria can become resistant.

That leads perfectly into the nursing process for anti -tuberculars.

We've touched on assessment checking liver enzymes, vision, hearing, but let's talk about interventions.

The text mentions DOT.

Direct Observation Therapy.

What is that?

It is exactly what it sounds like.

A healthcare worker, often a nurse or a public health aide, watches the patient swallow every single dose of the medication.

That seems intense.

Is that really necessary?

It feels a little authoritarian, I know.

But When you consider the stakes, yes.

Adherence is the biggest problem.

If a patient takes the med sporadically, they are basically breeding MDRTB in their own lungs.

And then they can spread that super strain.

Exactly.

To protect public health, we use DOT.

It can be in a clinic, at the patient's home, or sometimes even via a video call.

But we confirm the pills go down.

Speaking of administration, the text gives specific timing instructions for INH.

Yes.

Absorption matters.

INH is best absorbed on an empty stomach.

The guideline is one hour before or two hours after meals because food decreases the absorption rate.

But what if it upsets their stomach?

And that's the compromise.

INH can be tough on the stomach.

If the patient has severe GI upset, sometimes we allow it with a little food just to keep them compliant, but ideally empty stomach.

And one last practical tip from the text regarding lifestyle.

Sun safety.

Pyrazinamide and other drugs can cause photosensitivity.

Patients can get severe sunburns very easily.

They should use sunblock and avoid direct sunlight.

And also hygiene simple things like discarding tissues that contain sputum into a biohazard bag or flushing them and separating dishes to protect family members during that initial infectious phase.

Okay.

We have covered the resilient bacteria.

Let's leave the lungs for a moment and move to our second major category,

fungal infections.

The medical term is mycosis and the text divides these into yeasts and molds.

What is the big picture difference here?

Why is treating a fungus different from treating a bacteria?

It comes down to cell biology.

Bacteria are prokaryotes.

They're very simple cells.

Fungi are eukaryotes.

Their cells are structurally much more similar to our own human cells.

Which makes them harder to kill without hurting the patient.

That's the challenge.

Exactly.

It is very hard to find a drug that targets the fungus without causing collateral damage to the human host cells.

That's why antifungal drugs tend to have more side effects.

So what do we target?

Usually we target something called ergosterol, which is a sterile in the fungal cell membrane that humans don't have.

The text classifies these infections in two ways.

Local versus systemic and opportunistic versus primary.

Let's break that down.

Okay.

So local infections affect the mucous membranes, hair, nails, and moist skin.

Think of athlete's foot or oral thrush.

They're annoying, but usually not life -threatening.

And systemic.

Systemic infections are much, much more severe.

They involve the lungs, the central nervous system, or the abdomen.

These can kill you.

And opportunistic versus primary.

This is a key concept for understanding risk.

Primary fungal infections can happen to anyone.

You inhale spores from bird droppings or soil -like histoplasmosis, and you can get a lung infection even if you're healthy.

But opportunistic infections, these are the bullies.

They attack the weak.

We're talking about things like Candida albicans.

Right.

Candida is part of our normal flora.

It lives in your mouth and gut right now.

But if you wipe out your good bacteria with a course of antibiotics, or if your immune system crashes from chemotherapy or HIV, the Candida seizes the opportunity.

It overgrows.

That's an opportunistic infection.

Let's look at the drugs.

The text categorizes them into polyenies, azoles, and echinocandins.

Let's start with the polyenies, and specifically the drug that is arguably the most feared in the nursing arsenal.

Chemfotericin B.

Amphoteribol.

That is the nickname, and it is well -earned.

This is the heavy artillery.

We only use it for severe, life -threatening systemic fungal infections.

Why is it called Amphoteribol?

Because of its toxicity profile.

First, it is nephrotoxic to almost everyone.

It causes vasoconstriction in the kidneys.

If you are on Amphobie, your kidneys are taking a serious beating.

You have to monitor urine output, BUN, and creatinine religiously.

And it creates electrolyte chaos.

Total chaos.

It acts like a sieve in the kidneys, letting potassium and magnesium just leak right out.

Hypokalemia and hypomagnesemia are major risks, which can then lead to cardiac arrhythmias.

So you're constantly chasing and replacing electrolytes.

But there's also the immediate reaction, right?

The infusion reaction.

Oh, yeah.

The shake and bake.

Yeah.

Within one to three hours of starting the IV, patients can get high fevers, violent chills, we call them rigors flushing, and hypotension.

It honestly looks like they're going into septic shock.

So what does the nurse do?

We can't just let the patient suffer through that.

No, we pre -medicate.

The text outlines a specific protocol for this.

About 30 to 60 minutes before the infusion, we administer acetaminophen to help with the fever,

diphenhydramine, benadryl, to block the histamine reaction, and often hydrocortisone, which is a steroid, to dampen the inflammation.

That is a crucial clinical pearl.

Pre -medicate for amphobie.

The other polyane mentioned is nistatin.

This one seems much, much gentler.

Oh, way gentler.

Nistatin is too toxic to be given IV, so we only use it for local infections.

It is the go -to for Candida infections, like oral thrush.

And the administration method is memorable.

Swish and swallow.

Exactly.

For oral thrush, the patient takes the liquid suspension, swishes it around their mouth for several minutes to coat all the white patches, which is the fungus, and they swallow it.

Why swallow if the infection is in the mouth?

Because if you have thrush in your mouth, you very likely have it in your esophagus, too.

Nistatin is poorly absorbed by the GI tract, which is a good thing here.

It just coats the esophagus and gut, kills the fungus on contact, and then passes out in the stool.

Moving on to the azoles.

The prototype here is Fuconazole.

The azoles are a versatile group.

Fuconazole, or deflucan, really revolutionized antifungal treatment.

It's effective, it can be taken orally, and it's much less toxic than Amphotericin B.

It's used for everything from vaginal yeast infections to cryptococcal meningitis.

But it's not without baggage.

What's the major nursing alert for Fuconazole?

Drug interactions.

The azoles inhibit this CYP450 enzyme system.

Remember how rifampin induced the system?

It revved it up.

Right.

Fuconazole does the opposite.

It inhibits it.

So it handcuffs the liver enzymes.

Exactly.

So the liver stops metabolizing other drugs efficiently.

This causes those other drugs to build up to toxic levels in the blood.

What are the specific examples the text highlights?

Warfarin is the big one.

If you give Fuconazole to a patient on warfarin, their INR will skyrocket and they will be at a massive risk for bleeding.

Wow.

It also increases levels of funytoin, which is for seizures, and can cause severe hypoglycemia in patients taking sulfonylureas

So if your patient is on blood thinners or diabetic meds, you need to be hypervigilant when starting Fuconazole.

Absolutely.

You have to scrub the medication list for any and all interactions.

And one more group to mention quickly, the Echinocandins.

Drugs like caspifungin and mycifungin.

These are the newer class.

They inhibit the synthesis of the fungal cell wall.

They are IV only.

They are generally well tolerated.

But the main nursing consideration here is the IV site itself.

They can cause phlebitis, so you have to watch for redness or swelling at the insertion site.

Let's synthesize the nursing process for antifungals.

Assessment seems to revolve around the kidneys and liver.

Correct.

Before starting any of these drugs, especially the systemic ones, you need a baseline for BUN, creatinine, and liver enzymes.

And you keep checking them throughout the therapy.

And for interventions?

Monitor urine output.

If the kidneys take a hit from amphotericin B, you will see output drop.

That's a huge red flag.

Also,

safety regarding alcohol patients should avoid it to spare the liver.

Anything else?

And interestingly, the text mentions that some antifungals can cause visual changes or dizziness, so caution with driving is a necessary education point.

Okay, we have covered the resilient bacteria and the opportunistic fungi.

Now let's tackle the third and final section.

Viral infections, the intracellular hijackers.

Viruses are fascinating and terrifying.

They are obligate intracellular organisms.

They cannot survive or reproduce on their own.

They have to get inside your cell, uncoat their genetic material, and then hijack your cell's machinery to print more copies of the virus.

Which creates a huge pharmacological challenge.

Right.

How do you kill the virus without killing the host cell it is hiding inside?

That's why we have so many fewer antivirals compared to antibiotics.

The text notes that many viral illnesses, like the common cold, are self -limiting.

We just let them run their course.

But for influenza, herpes, and hepatitis, we intervene.

Let's start with influenza, the flu.

Highly contagious droplet transmission.

We all know the symptoms.

Abrupt onset of fever, headache, myalgia.

But here is the critical piece of pathophysiology for treatment.

Viral replication begins 24 hours before symptoms even appear.

So you are spreading it before you even know you are sick.

Exactly.

And that timing dictates the entire treatment strategy.

We use neuraminidase inhibitors like oseltamivir, which most people know as tomofluenzonomivir.

And what is the window for these drugs?

The 48 -hour rule.

These drugs must be started within 48 hours of symptom onset.

If you wait longer, they are basically not effective.

Why is that?

Because by 48 hours, the viral load has peaked.

The horse has already left the barn.

These drugs work by decreasing the release of the virus from infected cells.

If the virus has already spread everywhere, blocking the release doesn't help much.

And do they cure the flu?

No, not at all.

They might shorten the duration of symptoms by maybe a day, maybe two.

And the text makes a very bold point.

These drugs are not a substitute for the vaccine.

Prevention is still the primary goal.

Next up, herpesviruses.

This is a large family of viruses.

It is.

A family that stays with you forever.

We have HSV1, usually associated with cold sores.

HSV2, usually associated with genital lesions.

And then varitella zoster virus, or VZV, which causes chickenpox and can reactivate as shingles.

And the text also mentions CMV.

Cytomegalovirus, yes.

In healthy people, CMV is often silent.

But in immunocompromised patients, like those with AIDS, it can cause retinitis.

It attacks the retina and can lead to blindness.

The primary drugs here are the non -HIV antivirals, specifically nucleoside analogs.

The prototype is acyclover.

Acyclover is the workhorse for HSV1, HSV2, and shingles.

It interferes with viral DNA synthesis.

Essentially, it mimics a DNA building block.

Oh, it's a decoy.

A perfect decoy.

When the virus tries to build its DNA, it grabs the acyclover molecule by mistake, and the DNA chain terminates.

The virus can't replicate.

What are the side effects we need to manage?

Common ones are GI distress and headache.

But the major adverse reaction, the one you have to know for your exams, is nephrotoxicity.

Acyclover has low solubility.

If the patient is dehydrated, the drug can precipitate in the renal tubules.

It forms crystals in the kidneys.

Yes, crystallization.

It's like having tiny shards of glass in your kidney tubules.

It can cause acute kidney injury.

That sounds incredibly painful and damaging.

So what is the nursing implication?

Hydration.

Massive hydration.

Patients must have adequate fluid intake during therapy to flush the kidneys.

If you are giving it IV, you administer it slowly over at least 60 minutes.

You never ever give it as a bolus.

Because a bolus would just overwhelm the kidneys.

Exactly.

It increases the concentration in the kidney way too fast, leading to that crystallization.

The text also mentions a side effect called orthostatic hypotension with acyclover.

Yes.

We need to warn patients to stand up slowly.

Dizziness upon standing is a real risk, which of course creates a fall risk.

Now for CMV specifically,

the text lists gansaclover.

Is that similar to acyclovir?

It's in the same family, but gansaclovir has a major toxicity warning that acyclover doesn't.

Bone marrow suppression.

So we are watching the blood counts.

All of them.

Thrombocytopenia, which is low platelets, and leukopenia, which is low white blood cells.

You have to monitor the complete blood count, the CBC, very closely.

If the platelets drop too low, the patient is at risk for spontaneous bleeding.

Finally, let's talk hepatitis.

The liver viruses.

HPV and HDV.

Both cause chronic liver inflammation, cirrhosis, and can lead to liver cancer.

But the treatment goals differ because of the nature of the viruses themselves.

Let's start with hepatitis B.

Hepatitis B is a DNA virus.

We have a great vaccine for it, which is the first line of defense.

But if someone has chronic HPV, the treatment goal is usually viral suppression, not a cure.

We want to stop the virus from replicating to save the liver.

The drugs listed are tenofovir and enicovir.

Right.

And a critical nursing point.

Sudden stoppage of these drugs can cause a severe exacerbation of hepatitis B.

Acute exacerbation?

What does that mean?

It means if the patient just quits the meds, maybe they lose their insurance or just get tired of taking pills, the virus can rebound aggressively.

The liver inflammation spikes and it can be fatal.

So patient education is vital.

It's everything.

Do not stop this drug without supervision from your provider.

Now hepatitis C, this is an RNA virus.

And here the story has changed dramatically in recent years.

This is one of the biggest success stories in modern medicine.

There is no vaccine for hep C.

However,

we now have drugs that can actually cure HCV.

That is a huge distinction.

Suppression for hep B, but a cure for hep C.

Exactly.

The text mentions newer combination therapies like sofasbuvir and ledipasvir.

These are direct acting antivirals.

They target the viral replication machinery with incredible precision.

We are talking about high cure rates.

Over 95 % cure rates with just a 12 -week course of pills.

It used to be treated with interferon, which was miserable and had low success rates.

This is a complete game changer.

But before treatment, the text mentioned something called genotyping.

Hepatitis C has at least six distinct genotypes or strains.

The specific drug regimen and the duration of treatment depend on which genotype the patient has.

So you test the genotype first, then you treat.

Let's pull this all together with the clinical judgment case study provided in the text.

This is where we see if we can apply what we've learned.

The scenario is a 41 -year -old homeless male.

He is an alcohol user and he presents with a cough and night sweats.

Classic symptoms.

And the lab confirms positive acid -fast bacilli smear.

So it's active TB.

This is a textbook presentation if I've ever seen one.

The regimen ordered is INH, riffampin, and pyrazinamide daily for two months, followed by INH and riffampin biweekly for four to seven months.

A standard protocol.

Now let's connect the dots.

As the nurse, what are your primary concerns for this specific patient?

Okay, first, risk factors.

Homelessness suggests he might have been staying in crowded shelters, those congregate settings we talked about, and the alcohol use suppresses his immune system.

Exactly.

Now consider the adverse risks.

He is taking INH, riffampin, and PZA.

All three of those are hepatotoxic.

He is also an alcohol user, which is also hepatotoxic.

That is a double hit to the liver.

It's a massive assault on the liver.

So monitoring AST and ALT is non -negotiable here.

We need a baseline immediately.

Also, think about his nutritional status.

People who use alcohol heavily are often malnourished.

And deficient in B vitamins.

So he is at extreme risk for peripheral neuropathy from the INH.

Correct.

He absolutely needs that vitamin B6, the pyridoxin supplementation.

If we don't give it to him, he will develop painful nerve damage, which might just make him stop taking the TB meds altogether.

And then there's the compliance hurdle.

He is homeless.

How does he manage a nine -month regimen?

How does he store his meds?

How does he even remember to take them?

This is where the nurse's role extends beyond the hospital walls.

Case management, social support, and DOT direct observation therapy are going to be the only way to ensure he completes this treatment.

You can't just hand him a script.

If we just hand him a script and say, good luck, he won't finish.

He will develop resistant TB and be back in the ER in six months, sicker than he was before.

And how do we know the treatment is working?

It's not just about how he feels.

We need objective data.

We look for negative sputum cultures.

Usually, we look for negative tests two to three months after starting treatment, along with an improved chest x -ray showing the lungs are clearing up.

This chapter really covers a massive amount of ground.

Let's do a final summary for our listeners.

OK, let's break it down by pathogen.

Tuberculosis.

It's a long game.

Six to nine months.

Multi -drug therapy, R -E -P -E, is mandatory to prevent resistance.

Watch the liver.

Hepatotoxicity for all of them.

Watch the nerve's neuropathy with INH.

And remember to give vitamin B6.

Watch the eyes with ethambutol.

And warn the patient about the orange tears from rifampin.

Don't forget the orange tears.

Fun guy.

We have the local swish and swallow nest statin, and we have the systemic heavy -hitter amphotericin B.

If you are giving ampho -B, watch the kidneys and electrolytes like a hawk.

And pre -medicate with acetaminophen, benadryl, and steroids to stop that shake -and -bake infusion reaction.

And for fluconazole?

Watch out for drug interactions, especially with warfarin.

Viruses?

Timing is everything.

Tamiflu only works within the first 48 hours of flu symptoms.

For herpes drugs like acyclover, hydration is key to prevent kidney crystals.

And for hepatitis, note the difference.

Hepatitis B is about suppression.

Hepatitis C is about a cure.

But you have to genotype the virus first.

Before we sign off, we'd like to leave you with a provocative thought.

Something to mull over.

For me, looking at this chapter, the concept that really stands out is latency.

Both TB and herpes viruses have this terrifying ability to just hide in the body.

Waiting.

Just waiting.

TB can sit in the lungs for decades, walled off in a granuloma.

Chickenpox hides in the nerve ganglia and comes roaring back years later as shingles.

It really challenges the idea of what it means to be cured.

It does.

It highlights that asymptomatic does not always mean free of disease.

The pathogen is still there, just waiting for the immune system to slip.

It reminds us that a patient's history, even history from 20 or 30 years ago, is absolutely vital to their current care.

As nurses, we're the ones who have to ask those questions and connect those dots.

That is a powerful takeaway.

Thank you for listening to this deep dive into chapter 30.

We know it was a beast, but hopefully it's a little clearer now.

A huge thank you from all of us on the Last Minute Lecture theme.

Good luck on your exams and in your clinicals.

You've got this.

See you next time.